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ABSTRACT
Objectives: The purpose of the present study was to systematically review the literature on the surgical regenerative treatment 
of the peri-implantitis and to determine an effective therapeutic predictable option for their clinical management.
Material and Methods: The study searched MEDLINE and EMBASE databases from 2006 to 2016. Clinical human studies 
that had reported changes in probing depth (PD) and/or bleeding on probing (BOP) and/or radiologic marginal bone level 
(RBL) changes after peri-implantitis surgical treatment at 12-month follow-up or longer were included accordingly to PRISMA 
guidelines.
Results: The initial search obtained 883 citations. After screening and determination of eligibility, 18 articles were included 
in the review. The meta-analysis of selected studies revealed that the weighted mean RBL fill was 1.97 mm (95% confidence 
interval [CI] = 1.58 to 2.35 mm), PD reduction was 2.78 mm (95% CI = 2.31 to 3.25 mm), and BOP reduced by 52.5% (95% 
CI = 41.6 to 63.1%). Defect fill in studies using and not using barrier membranes for graft coverage was 1.86 mm (95% 
CI = 1.36 to 2.36 mm) and 2.12 mm (95% CI = 1.46 to 2.78 mm) correspondingly. High heterogeneity among the studies 
regarding defects morphology, surgical protocols, and selection of biomaterials were found.
Conclusions: All included studies underlined an improvement of clinical conditions after the surgical regenerative treatment 
of peri-implantitis, however, there is a lack of scientific evidence in the literature regarding the superiority of the regenerative 
versus non-regenerative surgical treatment. The presence of a barrier membrane or submergence in the regenerative procedure 
does not seem to be fundamental in order to obtain clinical success of the surgery.
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INTRODUCTION
In the recent years, dental implant rehabilitation 
has confronted requests for optimal functional and 
aesthetic outcomes which require an inflammation 
of the predictable surgical techniques and long-term 
clinical results. Besides of the successful functioning 
on a long-term, several types of complications have 
been recently encountered. The clinical condition 
involving dental implants, characterized by the 
inflammation, bleeding, suppuration of peri-implant 
tissues and rapid bone loss is widely known as peri-
implantitis [1-6].
Peri-implantitis is associated with the presence of a 
sub-marginal plaque, which contains a large variety 
of Gram-negative anaerobic rods, fusiform bacteria, 
motile and curved rods and spirochetes [7]. It contains 
large amounts of densely packed inflammatory cells 
(neutrophilis, macrophages, lymphocytes and plasma 
cells), frequently accompanied by a crater like bone 
defects that surround the contaminated implant 
[8,9]. Several lines of evidence indicated that an 
accumulation of bacteria on the implant surface plays 
an important role in the aetiology of peri-implantitis – 
an inflammatory condition affecting the tissues around 
osseointegrated implants, leading to loss of supporting 
bone [10]. Nevertheless, peri-implant tissues can be 
kept in a healthy clinical state and some endosseous 
implants successfully used as prosthetic abutments 
for the oral rehabilitation of fully and partially 
edentulous patients for a prolonged period of time 
[11]. Besides of a numerous patient-related factors 
(insufficient bone quality, smoking, systemic diseases 
or chemotherapy), surgical trauma or bacterial 
contamination during implant insertion, non-fit dental 
implant prosthesis and abnormal masticatory load 
are reported to be the most important causes of early 
implant failure [12-14].
Peri-implantitis can be defined as a site-specific 
infectious disease associated to an inflammatory 
process involving periodontal soft tissues, and 
causing bone loss around an osseointegrated implant. 
Numerous aetiological factors may play a decisive 
role for the progress of peri-implant infection. 
The implant design, the degree of roughness, the 
external morphology, the abutment connection, 
the passivation of the prosthesis and excessive 
mechanical load are all related with the disease 
[6,15]. Diagnosis can be referred on altered clinical 
condition like the colour in the gingiva, bleeding 
on probing (BOP), increased probing depth (PD), 
suppuration, and gradual loss of peri-implant bone as 
diagnosed by decrease of radiologic bone level (RBL) 
in standardized radiography.
The diagnosis and therapies for the soft tissue 
inflammation and peri-implant bone loss is quite 
challenging for the clinician. Diagnostic measures, 
such as probing pocket depth, radiographic tools, 
and microbial sampling have been shifted from the 
periodontal area and utilized during the maintenance 
phase of the dental implant treatment [16]. The main 
aim in the treatment of peri-implantis is to arrest 
the progression of the disease and at the same time 
to keep the dental implant in function solving the 
inflammatory signs of bleeding and pain [17]. Peri-
implant bony defects around dental implants can be 
treated with either non-surgical or surgical (resective 
or regenerative) techniques. Bone tissue regeneration 
is the objective therapeutic option in selected peri-
implant bony defects of functioning implants if 
appropriate surgical techniques are utilized and the 
aetiologic cause is fully eradicated [18]. 
The purpose of this systematic review is to screen 
recent literature on various approaches of surgical 
regenerative treatment of peri-implantitis in order to 
give the clinicians valuable suggestions for the most 
appropriate treatment modality.
MATERIAL AND METHODS
Protocol and registration
The methods of the analysis and inclusion criteria 
were specified in advance and documented in a 
protocol. The review was registered in PROSPERO, 
an international prospective register of systematic 
reviews. The protocol can be accessed through the 
following link:
http://www.crd.york.ac.uk/PROSPERO/display_
record.asp?ID=CRD42016033664
Registration number: CRD42016033664.
The reporting of this systematic analysis adhered to 
the Preferred Reporting Items for Systematic Review 
and Meta-Analyses (PRISMA) statement [19].
Focus question
The following focus questions were developed 
according to the population, intervention, comparison, 
and outcome (PICO) study design: 
1. What are the overall treatment outcomes of 
reconstructive procedures in treating peri-
implantitis? 
2. Does the use of barrier membranes or 
submergence of the healing site provide beneficial 
clinical outcomes in the treatment of peri-
implantitis?
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Information sources
The search strategy incorporated examinations of 
electronic databases, supplemented by hand searches. 
A search of four electronic databases, including Ovid 
MEDLINE, PubMed, EMBASE, and Dentistry and 
Oral Sciences Source was carried out for relevant 
studies published in the English language from 
January 2006 to March 2016. 
Additionally, a hand search performed in dental 
and implant-related journals limited to English 
language for the same period included: 1) “Journal 
of Periodontology”; 2) “Clinical Implant Dentistry 
and Related Research”; 3) “International Journal 
of Oral and Maxillofacial Implants”; 4) “Clinical 
Oral Implants Research”; 5) “Implant Dentistry”; 
6) “International Journal of Oral and Maxillofacial 
Surgery”; 7) “Journal of Oral and Maxillofacial 
Surgery”; 8) “Journal of Dental Research”; 9) 
“Journal of Prosthetic Dentistry”; 10) “International 
Journal of Prosthodontics”; 11) “Journal of 
Oral Implantology”; 12) “Journal of Clinical 
Periodontology”; 13) “International Journal of 
Periodontics & Restorative Dentistry”; 14) “European 
Journal of Oral Implantology”. A hand search of the 
reference lists in the articles retrieved was carried 
out to source additional relevant publications and to 
improve the sensitivity of the search.
Search
The keywords used in the search of the selected 
electronic databases included the following: “peri-
implantitis” OR “periimplantitis” OR “peri-implant” 
OR “periimplant” or (“implant” AND “failure”) 
AND “surgery” OR “surgical” OR “regeneration” 
OR “regenerative” OR “treatment” OR “therapy” OR 
“bone graft” OR “bone substitute” OR “laser” OR 
“lasers”.
The choice of keywords was intended to be extensive, 
to collect as much relevant data as possible without 
relying on electronic means alone to refine the search 
results.
Selection of studies
The resulting articles were independently subjected to 
clear inclusion and exclusion criteria by 2 independent 
reviewers as follows. Reviewers compared decisions 
and resolved differences through discussion, 
consulting a third party when consensus could not 
be reached. The third party was an experienced 
senior reviewer. The level of agreement between the 
reviewers regarding study inclusion was calculated 
using κ statistics. At the title and abstract stage, one 
reviewer accepted the citations that appeared to meet 
inclusion criteria and send them to full-text review, 
with a second reviewer assessing only those citations 
and abstracts that the first reviewer deemed ineligible. 
At the stage of reviewing of full-text articles, 
a complete independent dual review was undertaken.
Types of publications
The review included studies on humans published in 
the English language. Letters, editorials, case reports, 
literature reviews, and PhD theses were excluded. 
Types of studies
The review included all human prospective and 
retrospective follow-up studies and clinical trials, 
cohort studies, case-control studies, and case series 
studies on surgical regenerative treatment of peri-
implantitis, published between January 2006 and 
March 2016.
Types of participants/population
Subjects in the included studies must have had at least 
one osseointegrated titanium screw-shaped dental 
implant that presented signs of peri-implantitis.
Disease definition
The authors of this review classified the case 
definition of peri-implantitis of each study, if there 
was a clear radiographic threshold > 2 mm of 
continuous marginal bone loss beyond biologic peri-
implant bone remodelling, presence of BOP and/or 
suppuration on probing with probing depth more than 
6 mm [20].
Inclusion and exclusion criteria
The full text of all studies of possible relevance 
was obtained for assessment against the following 
inclusion criteria:
• Investigated surgical regenerative treatment in 
patients with at least one osseointegrated titanium 
screw-shaped dental implant, that presented signs 
of peri-implantitis;
• Studies involving at least one surgical 
regenerative treatment method of peri-implantitis 
applied;
• All human prospective or retrospective follow-
up studies and clinical trials, cohort studies, 
case-control studies, and case series studies 
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with a minimal sample size of 10 implants and 
not less than 12 months follow-up after surgical 
regenerative treatment of peri-implantitis;
• Clear report on clinical and radiographic peri-
implant tissues changes, including RBL and/or PD
change as primary outcome measure and/or BOP
as secondary outcome measure.
The applied exclusion criteria for studies were as 
follows:
• Animal or in vitro studies;
• Studies involving patients with specific diseases,
immunologic disorders, uncontrolled diabetes
mellitus, osteoporosis, or other implant risk
related systemic conditions;
• Studies investigating ceramic or coated surface
implants;
• Not enough information regarding the selected
topic;
• No access to the title and abstract in English
language.
Sequential search strategy
Following the initial literature search, all article titles 
were screened to eliminate irrelevant publications, 
considering the exclusion criteria. Next, studies were 
excluded based on data obtained from screening 
the abstracts. The final stage of screening involved 
reading the full texts to confirm each study’s 
eligibility, based on the inclusion criteria.
Data extraction
The data were independently extracted from studies 
in the form of variables, according to the aims and 
themes of the present review, as listed onwards.
Data items
Data were collected from the included articles and 
arranged in the following fields:
• “Author (Year)” – revealed the author and year of
publication.
• “Type of study” – indicated the type of the study.
• “Sample size” – described the number of patients
examined.
• “Detoxification method” – described additional
implant surface detoxification measures applied
in addition to the instrumental debridement, full
thickness flap, and degranulation.
• “Bone substitute/membrane” – described types of
bone grafts and membranes used for regeneration.
• “Antimicrobial” – described antimicrobial agents
(e.g. systemic antibiotics, chlorhexidine mouth
rinse) used adjunctive to the surgery.
• “Follow-up” – described the duration of the
observed outcomes after applied surgical
regenerative treatment of peri-implantitis.
• “Probing depth change (ΔPD)” – described
probing depth difference (in mm) before and after
surgical treatment.
• “Bleeding on probing change (ΔBOP)” –
described BOP difference (in %) before and after
surgical treatment.
• “Radiologic bone level change (ΔRBL)” –
described the marginal bone level difference
(in mm; measured from implant shoulder to the
bone surface) before and after the treatment;
and/or intrabony defect depth difference (in mm;
measured from the bottom of the defect to the
interproximal bone) before and after treatment.
Risk of bias assessment
Assessment of risk of bias was undertaken 
independently, and in duplicate by the two authors 
during the data extraction process. For the included 
studies, this was conducted using the Cochrane 
Collaboration’s two-part tool for assessing risk of bias 
[21].
The following possible sources of bias were 
addressed: random sequence generation (selection 
bias); allocation concealment (selection bias); 
blinding of participants and personnel (performance 
bias and detection bias); incomplete outcome data 
(attrition bias);
selective reporting (reporting bias); and other 
bias (examiner blinding, examiner calibration, 
standardized probing force, standardized radiographic 
assessment). The authors’ judgment for each source 
of bias item was assigned for each study in the data 
extraction table (Table 1). An overall risk of bias was 
then assigned to each trial according to Higgins et al. 
[21]. The degrees of bias were categorized as follows: 
low risk, if all the criteria were met; moderate risk, 
when only one criterion was missing; high risk, if two 
or more criteria were missing; and unclear risk, if too 
few details were available to make a judgement of 
certain risk assessment.
Statistical analysis
A meta-analysis was performed to integrate the 
quantitative findings from separate but similar studies 
and to provide a numerical estimate to the overall 
effect of interest. All meta-analyses were performed 
on studies that reported the clinical and/or radiologic 
outcomes of regenerative peri-implantitis treatment 
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approach. The primary outcome measures were ΔRBL 
and/or ΔPD, evaluating ΔBOP as secondary outcome 
measure. The pooled weighted mean (WM) and the 
95% confidence interval (CI) of each measure were 
estimated with Comprehensive Meta-analysis (Version 
2, Biostat, Englewood, NJ, USA) statistical software. 
Parametric data were expressed as mean and standard 
deviation (M [SD]). The random effect model was 
applied when performing meta-analysis to account 
for methodologic differences among studies. Forest 
plots were produced to graphically represent WM 
and 95% CI for the primary and secondary outcomes, 
with the implant as the analysis unit. Heterogeneity 
was assessed with the I2 test. To evaluate the 
potential influences of different treatment modalities, 
WM and 95% CI were calculated separately for 
membrane use, and type of the flap manipulation 
(submerged/nonsubmerged healing). The reporting 
of this meta-analysis adhered to the PRISMA 
statement [19].
RESULTS
Study selection
Article review and data extraction were performed 
according to PRISMA flow diagram (Figure 1). 
The initial electronic and hand search retrieved 883 
citations, 802 of which were eliminated as duplicates 
or not relevant articles. After titles and abstracts were 
reviewed, additional 34 articles were filtered as having 
not enough information regarding selecting topic. 
47 articles were identified as full-text articles, 18 of 
which were included in this review [22-39]. Reasons 
for studies exclusion after full-text assessment were 
as follows: no minimum 12 months follow-up (n = 7) 
[40-46]; a review paper (n = 3) [47-49], single case 
report presented (n = 15) [50-64]; methodological 
and design faults (n = 4) [66-69]. The κ value for the 
interreviewer agreement of the included publications 
was 0.92. 
Study characteristics
Eight prospective clinical studies [22,23,28,29,34, 
36,38,39], seven case series [24-27,30,33,35], and 
three randomized clinical trials (RCTs) [31,32,37] 
were included for the final review. A total of 528 
patients (713 implants) were treated. The mean age 
of the patients was 61 years (ranged from 20 to 83 
years) with the mean observation period of 37 months 
(ranging from 12 to 236 months). Eleven studies [23-
25,27,29,31,32,35-37,39] reported smoking status 
of the patients, ranging from 14% [39] to 72% [36]. 
The summarized individual study characteristics are 
described in Table 2.
Table 1. Risk of bias within the studies
Study Year of publication
Random sequence 
generation
Allocation 
concealment Blinding
Incomplete 
outcome data
Selective 
reporting
Other 
bias
Deppe et al. [22] 2007 ? ? ? - + +
Roos-Jansåker et al. [23] 2007 ? ? + - ? +
Roos-Jansåker et al. [24] 2007 ? ? ? - ? +
Schwarz et al. [25] 2008 + ? + - ? +
Romanos et al. [26] 2008 ? ? ? - - -
Schwarz et al. [27] 2009 + ? + - ? +
Schwarz et al. [28] 2010 ? ? + - ? +
Roccuzzo et al. [29] 2011 ? ? + + ? +
Froum et al. [30] 2012 ? ? + - - -
Aghazadeh et al. [31] 2012 + - + + + +
Wohlfahrt et al. [32] 2012 + + + + + +
Wiltfang et al. [33] 2012 ? ? ? - - +
Schwarz et al. [34] 2013 + ? + ? - +
Matarasso et al. [35] 2014 ? ? ? - ? +
Roos-Jansåker et al. [36] 2014 ? ? + - ? +
Jepsen et al. [37] 2015 + + + + + +
Froum et al. [38] 2015 ? ? + + + -
Roccuzzo et al. [39] 2016 ? ? - + + +
+ = low risk; ? = unclear risk; - = high risk.
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Eight studies included rough surface dental implants 
[26,29,30,31,32,35,37,39], three studies investigated 
machined surface implants [23,24,36] and five studies 
- both rough and machined surface dental implants 
[22,25,27,28]. The remaining two studies did not 
reveal implant surface specifications [33,38].
Initial radiologic bone defect depth was measured 
in twelve studies [22-24,29-33,35-38]. In nine 
studies [22,29-33,35,37,38] the distance was 
measured from the implant shoulder to the first 
bone contact on dental radiographs with the mean 
from 3 to 8 mm [29,35]. In three studies [23,24,36] 
the measurement reference point of the radiologic 
defect depth was the first thread of the implant. 
The mean initial PD was measured clinically in 
all included studies, ranging from 4.8 to 8.8 mm 
[22,30]. After applied surgical regenerative treatment, 
the PD reduction was ranging from 1.1 to 5.4 mm 
[27,30]. All studies except three [22,26,32] provided 
BOP data: the mean initial BOP was ranging 
from 19.7 to 100% [35,30,34,38]. The mean BOP 
reduction from 25.9 to 91.1% was obtained after 
surgical regenerative treatment of peri-implantitis 
[28,38].
Figure 1. PRISMA flow diagram.
Data included 528 patients (713 implants) 
Ovid MEDLINE, PubMed, EMBASE, and Dentistry & Oral 
Sciences Source advanced search: 
- Search terms: “peri-implantitis” OR “periimplantitis” OR 
“peri-implant” OR “periimplant” or (“implant” AND “failure”) 
AND (“surgery” OR “surgical” OR “regeneration” OR 
“regenerative” OR “treatment” OR “therapy” OR “bone graft” 
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- Publication dates: 01/01/2006 – 01/03/2016 
- Species: Humans, In vivo 
- Languages: English 
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Table 2. Selected studies
Author Type of study
Sample size 
(implants)
Detoxification 
method Bone substitute/membrane Antimicrobial
Follow-
up
(months)
PD 
Mean (SD) mm BOP
+ Mean, % Radiologic bone level Mean (SD) mm Complications Comments Submerge
IN ΔPD IN ΔBOP IN ΔRBL
Deppe et al. 
[22]
Prospective 
clinical 
study
19 (6 patients)a No augmentation
20 - 236
5.1 (1.3) 0.8 (1.2)
No data No data
7.6 (1.4) 0.3 (1.3) 8 implants were lost in augmented 
bone groups due to infection and 5 
implants lost in non-augmented sites.
With the respect to the long term results of augmentation procedures, 
the method used for decontamination seems to play a subordinate role. 
Augmentation with 1:1 mix of AB and βTCP can lead to reduction of 
the defect depth.
Y15 (7 patients) AB mixed with βTCP 1:1/PTFE 4.8 (1.4) 2.3 (1.2) 6.8 (1.2) 2.1 (1.1)22 (10 patients)a CO2 laser
No augmentation 6.1 (1.6) 2.7 (1.5) 7.2 (1.3) 0.4 (1.1)
17 (9 patients) AB mixed with βTCP 1:1/PTFE 5 (1.3) 2.5 (1.3) 6.7 (1.5) 2.2 (1.3)
Roos-Jansåker 
et al. [23]
Prospective 
clinical 
study
29 (17 patients) 3% H2O2, Saline
FHA/SRM 0.1% CHX rinse for 5 weeks.Amx (375 mg x 3) + Metro 
(400 mg x 2) for 10 days.
12 5.4 (1.8) 2.9 (1) 79.3% 57.7% 3.4 (1.2) 1.5 (1.2)
Membrane exposure after 2 weeks 
was noted in 43.8% of the treated 
implants.
It is possible to treat peri-implant defects with a bone substitute, with 
or without a resorbable membrane. N
36 (19 patients) FHA 5.6 (1.8) 3.4 (1.7) 92.9% 67.9% 2.8 (0.8) 1.4 (1.3) Uneventful
Roos-Jansåker 
et al. [24] Case series 16 (12 patients) 3% H2O2, Saline FHA/SRM
0.1% CHX rinse for 5 weeks.
Amx (375 mg x 3) + Metro 
(400 mg x 2) for 10 days.
12 5.1 (1) 4.2 (1.5) 75% 62.5% 3.8 (1) 2.3 (1.2)
62.5% implant sites demonstrated 
inadequate primary healing with the 
presence of soft tissue craters.
Membrane exposure 75.1%
Treatment of peri-implantitis defect using a bone graft substitute 
combined with a resorbable membrane and submerged healing 
resulted in defect fill and clinical healthier situations.
Y
Schwarz et al. 
[25] Case series
11 (11 patients)
Saline
nanoHA
0.2% CHX rinse for 2 weeks. 24
6.9 (0.6) 1.5 (0.6) 80%; 36%
No data
Suppuration around 2 implants Both treatment procedures have shown efficacy, however, the 
application of natural bone mineral in combination with a collagen 
membrane may result in an improved outcome of healing.
N
11 (11 patients) BDX/CM 7.1 (0.8) 2.4 (0.8) 78% 44% N
Romanos et al. 
[26] Case series 19 (15 patients) CO2 laser AB or BDX/CM 27 6 (2) 3.5 (1.3) No data No data No data
Bovine xenograft provided more radiographic bone fill than 
autogenous graft, because of autogenous graft resorption over time. YN
Schwarz et al. 
[27] Case series
9 (9 patients)
Saline
nanoHA
0.2% CHX rinse for 2 weeks. 48
6.9 (0.6) 1.1 (0.3) 80% 32%
Decreased translucency in the former 
peri-implant defect area noticed at 8 
sites in nanoHA and 5 sites in BDX/
resorbable membrane group.
Uneventful
While the application of natural bone mineral with a collagen 
membrane resulted in clinical improvements, a long-term outcome 
obtained with nanocrystaline hydroxyapatite without a barrier 
membrane must be considered as poor.
N
10 (10 patients) BDX/CM 7.1 (0.7) 2.5 (0.9) 79% 51% N
Schwarz et al. 
[28]
Prospective 
clinical 
study
9 (9 patients)
Saline DBX/CM 0.2% CHX rinse for 2 weeks. 12
6.7 (0.7) 1.6 (0.9 81.5% 38.9%
No data Uneventful Defect configuration may have an impact on the clinical outcome following surgical regenerative therapy of peri-implantitis lesions. N9 (9 patients) 7.1 (0.6) 1.6 (0.7) 83.3% 25.9%9 (9 patients) 7 (0.5) 2.7 (0.7) 85.2% 61.1%
Roccuzzo et al. 
[29]
Prospective 
clinical 
study
14 TPS implants 
(14 patients)
24% EDTA gel, 1% 
CHX gel. Saline BDX
Axm and Clavulanic acid 
(1000 mg x 2) for 6 days.
0.2% CHX rinse for 3 weeks.
12
7.2 (1.5) 2.1 (1.2) 91.1% 33.9% 3.9 (1.6) 1.6 (0.7)
No complications
Clinical parameters around moderately rough implants were better 
than around rough implants.
Surgical regenerative technique described resulted in a clinical 
healthier situation around many of the treated implants so that their 
function could be fully maintained. Complete fill of the bony defect 
seems not to be a predictable result.
N12 SLA implants 
(12 patients) 6.8 (1.2) 3.4 (1.7) 75% 60.4% 3 (0.9) 1.9 (1.3)
Froum et al. 
[30] Case series 19 (15 patients)
AA, Saline, 
Tetracycline (50 
mg/mL), 0.12% 
CHX
DBX or MBA/Enamel matrix 
derivative/ /PDGF/CM or 
SCTG
Amx 500 mg x 3 for 10 days.
0.12% CHX rinse for 2 weeks. 36 - 90 8.8 (1.9) 5.4 (1.5) 100% 78.9% 6.4 (1.9) 3.8 (1.5)
Regenerative approach for the treatment of peri-implantitis appear to 
be encouraging. N
Aghazadeh et 
al. [31]
Randomized 
controlled 
clinical 
study
34 (22 patients)
3% H2O2, Saline
AB/resorbable bovine collagen Azithromycin (250 mg x1) for 
4 days.
0.1% CHX rinse for 6 weeks.
12
6 (1.3) 2 (1.2) 87.5% 44.8% 5.8 (1.7) 0.2 (1.8)
BDX provided more radiographic bone fill than AB. The success for 
both surgical regenerative procedures was limited. N37 (23 patients) BDX/resorbable bovine collagen 6.2 (1.4) 3.1 (1.2) 79.4% 50.4% 5.2 (1.8) 1.1 (1.9)
Wohlfahrt et 
al. [32]
Randomized 
clinical trial
16 (16 patients)
24% EDTA gel. 
Saline
Porous titanium granules 0.2% CHX rinse for 4 weeks.
Amx (500 mg x 3) + Metro 
(400 mg x 2) for 10 days.
12
6.5 (1.9) 1.7 (1.7) No data No data 6.8 (2.7) 2 (1.7)
Uneventful Reconstruction with porous titanium granules resulted in significantly 
better radiographic peri-implant defect fill compared with controls.
Y16 (16 patients)a No augmentation 6.5 (2.3) 2 (2.3) No data No data 6.8 (3.9) 0.1 (1.9)
Wiltfang et al. 
[33] Case series 36 (22 patients)
Implantoplsty, 20% 
Phosphoric Acid AB mixed with BDX 1:1
Ampicillin/sulbactam 1500 
mg preoperatively. 12 7.5 (1.8) 4 (1.8) 61% 36% 5.1 (2.4) 3.5 (2.4)
One local infection 1 week 
after surgery causing loss of the 
augmentation material without loss 
of the implant.
Surgical regenerative treatment provided a reliable method to reduce 
peri-implantitis induced bone defects. N
Schwarz et al. 
[34]
Prospective 
clinical 
study
7 (7 patients) Implantoplasty, Saline
BDX/CM
Non specified antibiotic 
medication for 5 days. 48
5.5 (1.7) 1.2 (1.9) 100% 85.2%
No data
Reinfection in 4 patients 
occurred between 24 - 36 months 
postoperatively.
A combined surgical respective/regenerative therapy of peri-
implantitis were not influenced by the method of surface 
decontamination.
N
10 (10 patients) Implantoplasty,
Er:YAG laser
5.1 (1.5) 1.3 (1.8) 95.2% 71.6%
Matarasso et 
al. [35] Case series 11 (11 patients)
Implantoplasty,
AA, Saline DBX/CM
Amx 875 mg and clavulanic 
acid 125 mg x 2 for 5 days.
0.12% CHX rinse for 4 weeks.
12 8.1 (1.8) 4.1 (1.5) 19.7% 13.6% 8 (3.7) 2.7 (3.3) Membrane exposure in 18% of cases.
Combined regenerative/resective surgical approach for the treatment 
of peri-implantitis defects yielded positive clinical and radiographic 
results after 12 months.
N
Roos-Jansåker 
et al. [36]
Prospective 
clinical 
study
23 (13 patients) 3% H2O2, Saline
FHA/SRM 0.1% CHX rinse for 5 weeks.Amx (375 mg x 3) + Metro 
(400 mg x 2) for 10 days.
60 5.6 (1.9) 3 (2.4) 75% 42.4% 4.6 (1.3) 1.5 (1.2) Membrane exposure The use of a resorbable membrane in combination with a bone 
substitute did not add to the predictability or extent of bone fill.
N
22 (12 patients) FHA 6 (2.2) 3.3 (2) 94.3% 82.9% 4 (0.8) 1.1 (1.2)
Jepsen et al. 
[37]
Randomized 
clinical trial
33 (33 patients)
Titanium brush, 3% 
H2O2, Saline
Porous titanium granules 0.2% CHX rinse for 4 weeks.
Amx (500 mg x 3) + Metro 
(400 mg x 2) for 8 days.
12
6.3 (1.3) 2.8 (1.3) 89.4% 56.1% 4.6 (2) 3.6 (2)
Uneventful
Reconstructive surgery using porous titanium granules resulted in 
significantly enhanced radiographic defect fill compared with open 
flap debridement. The radiographic findings must be interpreted with 
caution, because it is difficult to discern biomaterial and newly formed 
osseous tissue.
N
30 (30 patients)a No augmentation 6.3 (1.6) 2.6 (1.4) 85.8% 44.9% 4 (2.5) 1.1 (1.4) 
Froum et al. 
[38]
Prospective 
clinical 
study
168 (100 patients)
AA, Saline, 
Tetracycline (50 
mg/mL), 0.12% 
CHX
DBX or MBA/Enamel matrix 
derivative/ /PDGF/CM or 
SCTG
24 - 120 8.1 (2.5) 5.1 (2.2) 100% 91.1% 3.8 (2.3) 1.8 (2)
2 implants were lost at 6 months 
follow up 16.7% of cases needed 
additional surgeries to obtain desired 
result.
Regenerative protocol used in treating peri-implantitis produced 
positive clinical outcomes in terms of reduction in BOP and PD, bone 
gain, and implant survival.
N
Roccuzzo et al. 
[39]
Prospective 
clinical 
study
71 (71 patients)
Titanium brush, 
24% EDTA gel, 1% 
CHX gel. Saline
DBX
Axm and Clavulanic acid 
(1000 mg x 2) for 6 days.
0.2% CHX rinse for 3 weeks.
12 7.2 (1.6) 2.9 (1.7) 71.5% 53.2% No data No data
6 implants were explanted due to 
persistent pus formation after 12 
months.
Partial defect fill was obtained. Complete resolution does not seem a 
predictable outcome. N
aNon augmented control groups were excluded for evaluation.
NanoHA = nanocrystalline hydroxyapatite; BDX = bovine-derived xenograft; CHX = chlorhexidine solution; Saline = Sterile physiologic saline solution; FHA = fluorohydroxyapatite, Amx = Amoxicillin; Metro = Metronidazole; AB = autogenous bone; SCTG = Subepithelial connective tissue graft; 
PDGF = Platelet-derived growth factor; MBA = mineralized bone allograft; βTCP = beta tricalcium phosphate; CM = collagen membrane; PTFE = polytetrafluoroethylene membrane; SRM = synthetic resorbable membrane; AA = air abrasive.
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Figure 2A. Meta-analysis for radiologic bone level change (ΔRBL). The calculated WM was 1.97 mm (95% CI = 1.58 to 2.35 mm).
All included studies used grafting materials for 
peri-implant bone defect augmentation. Most 
commonly xenografts [25-31,34,35,38,39] were 
utilized as well as other grafting materials, including 
flourhydroxyapatites [23,24,36], autografts [26,31], 
allografts [30,39], porous titanium granules [32,37], 
and comixtures of several different grafts [22,33]. 
There were more study groups using barrier 
membranes [22-28,30,31,34-36,38], than study 
groups, without barrier membranes utilized to cover 
the grafted area [23,25,27,29,32,33,36,37,39]. 
Due to high heterogeneity of the studies, statistical 
comparisons among different grafting materials and 
membrane types were not intended. 
Risk of bias within studies
Summarizing the risk of bias for each study, most of 
the studies were classified as unclear risk [22-25,27-
29,34-36,38,39]. Two studies were considered as 
having low risk of bias [32,37], where as another one 
was classified as moderate risk [31], and three studies 
were attributed to high risk of bias [26,30,33]. The 
risk of bias assessment for the included studies is 
summarized in Table 1.
Results of meta-analysis
The results and forest plots of the meta-analyses 
for ΔRBL, ΔPD and ΔBOP are demonstrated 
in Figures 2 - 4.
Following surgical regenerative treatment of peri-
implantitis, the reported WM of ΔRBL was 1.97 
mm (95% CI = 1.58 to 2.35 mm; Figure 2A). WM 
of ΔRBL was 1.86 mm (95% CI = 1.36 to 2.36 mm; 
Figure 2B) in ten study groups with membranes used, 
whereas WM of ΔRBL was calculated 2.12 mm (95% 
CI = 1.46 to 2.78 mm; Figure 2C) in seven study 
groups without membranes used to cover the grafted 
area. ΔRBL in submerged healing cases was evaluated 
in four study groups, with WM 2.17 mm (95% CI = 
1.87 to 2.47 mm; Figure 2D), whereas thirteen groups 
of non-submerged healing presented WM 1.91 mm 
(95% CI = 1.44 to 2.39 mm; Figure 2E).
All included studies investigated probing depth 
change prior and post treatment. The pooled WM 
of ΔPD was 2.78 mm (95% CI = 2.31 to 3.25 mm; 
Figure 3A). WM of ΔPD 2.88 mm (95% CI = 2.31 to 
3.45 mm; Figure 3B) was calculated in eighteen study 
groups using the barrier membrane. Similarly, WM of 
ΔPD 2.6 mm (95% CI = 1.9 to 3.3 mm; Figure 3C) 
was obtained in ten study groups, without membranes 
used to cover the graft. In four study groups, that 
evaluated submerged healing, WM of ΔPD 2.68 mm 
(95% CI = 1.71 to 3.64 mm; Figure 3D) was obtained, 
meanwhile WM of ΔPD 2.77 mm (95% CI = 2.23 to 
3.3 mm; Figure 3E) was granted in twenty three study 
groups of non-submerged healing.
The percentage of BOP reduction was 
reported in fifteen studies, with the WM being 
55% (95% CI = 45.2 to 64.4%; Figure 4A). 
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Figure 2C. Meta-analysis for radiologic bone level change (ΔRBL) without membrane coverage of the grafted area.
The calculated WM was 2.12 mm (95% CI = 1.46 to 2.78 mm).
Figure 2D. Meta-analysis for radiologic bone level change (ΔRBL) in submerged peri-implant defect healing.
The calculated WM was 2.17 mm (95% CI = 1.87 to 2.47 mm).
Figure 2B. Meta-analysis for radiologic bone level change (ΔRBL) with membrane coverage of the grafted area.
The calculated WM was 1.86 mm (95% CI = 1.36 to 2.36 mm).
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Figure 3A. Meta-analysis for probing depth change (ΔPD).
The calculated WM was 2.78 mm (95% CI = 2.31 to 3.25 mm).
Figure 2E. Meta-analysis for radiologic bone level change (ΔRBL) in non-submerged peri-implant defect healing.
The calculated WM was 1.91 mm (95% CI = 1.44 to 2.39 mm).
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Figure 3C. Meta-analysis for probing depth change (ΔPD) without membrane coverage of the grafted area.
The calculated WM was 2.6 mm (95% CI = 1.9 to 3.3 mm).
Figure 3D. Meta-analysis for probing depth change (ΔPD) in submerged peri-implant defect healing.
The calculated WM was 2.68 mm (95% CI = 1.71 to 3.64 mm).
Figure 3B. Meta-analysis for probing depth change (ΔPD) with membrane coverage of the grafted area.
The calculated WM was 2.88 mm (95% CI = 2.31 to 3.45 mm).
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Figure 4A. Meta-analysis for bleeding on probing change (ΔBOP).
The calculated WM was 55% (95% CI = 45.2% to 64.4%).
Figure 3E. Meta-analysis for probing depth change (ΔPD) in non-submerged peri-implant defect healing.
The calculated WM was 2.77 mm (95% CI = 2.23 to 3.3 mm).
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Studies, with membranes used, exhibited WM of 
ΔBOP 56.5% (95% CI = 41.8 to 70.2%; Figure 4B). 
This was similar for studies, without membranes 
used for graft coverage, where WM of ΔBOP was 
52.5% (95% CI = 41.6 to 63.1%; Figure 4C). Due 
to low number of studies, investigating ΔBOP 
after submerged healing surgery, meta-analysis of 
submergence impact on ΔBOP was not conducted.
Risk of bias across studies
There were several limitations present in the current 
meta-analysis. Current review includes studies written 
in English only, which could introduce a publication 
bias. The included studies were of relatively short 
follow-up period and included relatively small 
numbers of patients. There were various degrees of 
heterogeneity in each study design, case selection, 
and treatment provided among studies. The absence 
of control groups was an important limitation. There 
was also too high heterogeneity of the selected studies 
to compare the impact of different bone grafting 
materials or membrane types for the final treatment 
outcome. 
Figure 4C. Meta-analysis for bleeding on probing change (ΔBOP) without membrane coverage of the grafted area.
The calculated WM was 52.5% (95% CI = 41.6% to 63.1%).
Figure 4B. Meta-analysis for bleeding on probing change (ΔBOP) with membrane coverage of the grafted area.
The calculated WM was 56.5% (95% CI = 41.8% to 70.2%).
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DISCUSSION
Peri-implantitis can be defined as a clinical condition 
characterized by an inflammatory reaction that 
involves the hard and soft tissue, which causes loss 
of supporting bone and pathological pocket formation 
surrounding the osseointegrated dental implants [1-
18]. Several therapies options have been developed in 
order to manage the peri-implantitis, which could be 
non-surgical or surgical [6,10,47-50]. 
A conservative treatment option may be useful in 
cases without bone loss and a pocket formation 
limited to 3 - 4 mm. In case of evident bone loss and 
pocket formation over 5 mm, the surgical treatment 
seems to be necessary [22-39]. Surgical techniques 
can be divided into resective and regenerative surgery 
[6,50]. 
The resective implant treatment attempts to eliminate 
the aetiologic factors and maintain optimal peri-
implant conditions, mainly by cleaning the surfaces 
of the implants; whereas regenerative therapy (using 
bone grafts, membranes and growth factors) aims to 
regenerate peri-implant bone defect and reconstruct 
the peri-implant unit to previously existing normal 
physiologic limits [6,47,49,50,66].
Romeo et al. [66] have compared the efficacy of 
resective surgery with that of implantoplasty. The 
results obtained after 3 years of therapy demonstrated 
that the marginal bone loss was significantly lower 
after implantoplasty and the surgical therapy without 
biomaterial results effective in case of deep peri-
implantitis. 
The present investigation aimed to screen what is 
published in the recent international literature on 
the overall treatment outcomes of reconstructive 
procedures in treating peri-implantitis. The application 
of bone grafting materials for peri-implant bone 
defect treatment was used in all the recorded studies 
[22-39]. The meta-analysis showed that 1.97 mm 
mean ΔRBL was gained after surgical regenerative 
treatment. The lowest bone fill (0.2 [1.8] mm) was 
obtained in the comparative study by Aghazadeh et al. 
[31] using autografts, which was similar in results of 
Deppe et al. [22] (0.3 [1.3] mm) and Wohlfahrt et al. 
[32] (0.1 [1.9] mm) study groups, where surgical non-
regenerative treatment was applied. Autogenous bone, 
which has been often defined as the “gold standard” 
in bone augmentation, shows a volume loss of 
approximately 40% during healing time. On the other 
hand, synthetic bone graft substitutes show a high 
stability in volume, but remain nearly or completely 
unresorbed even several years after surgery [70]. 
Recently, Araujo and Lindhe [71] demonstrated, that 
autologous bone neither stimulate nor retard new bone 
formation in beagle dog extraction socket model. This 
raises an open dispute, if autografts, despite of their 
osteoinductive and osteogenic properties, still might 
be described as “gold standard” in situations, where 
slow resorption and adequate space maintaining 
biomaterials are desired. In contrary, regeneration 
of peri-implant defects with autografts mixed 
with bovine bovine-derived xenograft [33] or beta 
tricalcium phosphate [22] exhibited 2.1 (1.1) mm and 
3.5 (2.4) mm peri-implant bone gain correspondingly. 
Decreased resorption rate and increased 
osteoconductivity of composite autograft mixture 
with synthetic or xenogenic matrials compared of 
autogratfs alone could influence this better outcome. 
However, it is important to note, that visual bone fill 
on the radiographs per se is barely sufficient to claim 
a successful long-term outcome after peri-implantitis 
treatment [72].
The highest ΔRBL aproximatelly 3.5 to 3.8 mm was 
reported in three studies (Froum et al. [30]; Wiltfang 
et al. [33]; Jepsen et al. [37]). Froum et al. [30] used 
enamel matrix derivative and platelet derived growth 
factor (PDGF) to enhance regenerative outcome. This 
might influence the increased bone fill, however well 
designed studies and long-term RCTs, comparing 
effectiveness of these bioactive materials on peri-
implant bone regeneration, currently are still lacking. 
Wilfang el al. [33] and Jepsen et al. [37] used bovine-
derived xenograft and porous titanium granules 
correspondingly to fill peri-implant bone defects. 
The above average ΔRBL, obtained in the latter two 
studies, should be also interpreted with caution, 
because both xenograft and porous titanium granules 
are highly radiopaque materials, and it is difficult to 
discern biomaterial and newly formed osseous tissue.
There were numerous surgical techniques described 
in the included articles of this review to regenerate 
the peri-implant bone defects, including various 
submergence protocols (e.g. submerged or non-
submerged healing), polytetrafluoroethylene (PTFE), 
collagen, synthetic membranes or no membrane 
used to cover the grafted area. Submergence of the 
healing site was employed in four study groups of the 
included articles [22,24,32]. The rest study groups 
included in this review applied non-submerged 
healing. The meta-analysis and comparison between 
submerged and non-submerged sites provided similar 
clinical outcomes, having mean ΔRBL 2.17 mm and 
1.91 mm alongside to the mean ΔPD 2.68 mm and 
2.77 mm in submerged and non-submerged sites 
correspondingly.
The use of barrier membrane to cover the grafted 
area is often an operator dependent decision. 
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Barrier membranes are intended to stabilize the graft 
and to prevent epithelial downgrowth and fibroblast 
transgrowth into the grafted area, thereby favouring 
the population of bone cells in a bony defect. In 
agreement to findings in this review, Sahrmann et al. 
[73] concluded that guided bone regeneration using 
both bone graft substitute and membrane represents 
the major part of published surgical regenerative 
treatment of peri-implantitis cases. Schwarz et al. 
[27] stated that combination of biomaterial (bovine-
derived xenograft) together with collagen membrane 
resulted in improved clinical outcomes compared to 
biomaterial (nanocrystalline hydroxyapatite) alone. 
However, in this study different biomaterials were 
used, therefore comparisons should be interpreted 
with caution. Another study of Schwarz et al. [28] 
have shown that the use of a bone graft with the 
additional placement of a membrane may be more 
efficient in specific bone lesions around implants, 
however well-defined crater-like defect may improve 
the retention of the bone graft without additional 
use of the barrier membrane thereby favouring the 
healing [27,36]. Further studies of Roos-Jansaker et 
al. [36,74] and systematic reviews by Figuero et al. 
and Chan et al. [75,76] concluded that the application 
of a barrier membrane is costly, time consuming, 
technique sensitive, related to high membrane 
exposure risk, and its application did not provided 
improved clinical outcome nor in the terms of RBL, 
neither PD or BOP. This is in agreement with findings 
of meta-analysis in this review, where mean ΔRBL 
was 1.86 mm versus 2.12 mm, mean ΔPD 2.88 mm 
versus 2.6 mm, and mean ΔBOP 56.5% versus 52.5% 
in case with and without membrane used for graft 
coverage correspondingly. These findings suggest that 
barrier membrane placement might be not necessary 
in well-contained peri-implant bone defects.
The meta-analysis revealed reduction of PD and 
BOP after surgical regenerative treatment of peri-
implantitis in all included studies, with mean ΔPD 
2.78 mm and mean ΔBOP 55%. Although surgical 
regenerative treatment resulted in a clinical healthier 
situation around treated implants, most of the included 
studies [23,24,28,29,31-33,35,37,39] had minimal 
12 months postoperative follow-up period to meet 
the borderline of the inclusion criteria. At the time 
there is very limited number of long-term RCTs, 
investigating the outcomes of surgical regenerative 
treatment of peri-implantitis [39,48]. Nevertheless, in 
real clinical situations when every treatment modality 
should be well applied and effective to treat peri-
implantis, the ethical concern is an important issue. 
Constantly, there were only three RCTs included in 
this systematic review with the longest 12 months 
follow-up [31,32,37]. Future years of observation are 
necessary to verify whether an osseous defect fill is 
adequate to ensure favourable long-term maintenance. 
A 6 months case series study published by of Schwarz 
et al. [40] concluded that both the application of 
alloplastic material (nanocrystalline hydroxyapatite) 
or bovine-derived xenograft covered with collagen 
membrane induce significant improvement in clinical 
parameters (probing depth, clinical attachment level) 
at the healing control. A continuing follow-up of the 
same study group in a 2-years outcomes published 
by Schwarz et al. [25] also underlined the successful 
bone filling of the peri-implant defect applying both 
with nanocrystalline hydroxyapatite and bovine-
derived xenograft in combination with collagen 
membrane that provided a significant reduction of the 
PD and gain in clinical attachment level. However, in 
the 4-year follow-up [27], the combination of bovine-
derived xenograft and collagen membrane were more 
clinically efficacious as compared to nanocrystalline 
hydroxyapatite alone. This difference might be 
influenced by different long-term physicochemical 
properties of the applied bone graft substitute. In 
this systematic review high heterogeneity among the 
studies regarding surgical protocols, and selection 
of biomaterials were found, therefore at the time no 
clear recommendations could be drawn, how various 
treatment modalities or grafting materials could 
influence the clinical outcomes on the long-term basis.
Limitations
Even if a comprehensive and complete investigation 
of the effects of surgical therapies has been 
performed, there were some limitations to this 
systematic review. Surgical regenerative treatment of 
peri-implantitis is a complex procedure, depending 
on various multiple factors, including patient 
general health condition, oral hygiene habits, defect 
configuration, implant surface characteristics, 
decontamination procedure, surgical technique, 
postoperative maintenance program, and various other 
factors which are not possible to fit within the frames 
of systematic literature review and meta-analysis.
CONCLUSIONS
Within the limits of this systematic review, surgical 
regenerative treatment is a predictable option in 
managing peri-implantitis and improving clinical 
parameters of peri-implant tissues. There is no 
fundamental advantage of membrane use for bone 
graft coverage or submergence of the healing site on 
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the final outcome of peri-implant defect regeneration.
Due to the limited number of randomized clinical 
trials, at the time there is a lack of scientific 
evidence in the literature regarding the superiority 
of the regenerative versus non-regenerative surgical 
treatment. No conclusions could be drawn regarding 
the choice of biomaterials for peri-implant bone 
regeneration due to high heterogeneity among the 
present studies. Further well designed long-term 
randomized clinical trials, investigating the impact 
of peri-implant defect configuration, application 
of different grafting materials and bioactive 
modifiers, implant surface decontamination methods, 
and various surgical protocols on the final outcome of 
the regenerative procedure are needed.
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